<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/latestarticles/journal?journal=bmcdermatol&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Dermatology - Latest Articles</title>
        <link>http://www.biomedcentral.com/bmcdermatol/</link>
        <description>The latest research articles published by BMC Dermatology</description>
        <dc:date>2009-11-12T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/9/11" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/9/10" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/9/9" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/9/8" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/9/7" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/9/6" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/9/5" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/9/4" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/9/3" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/9/2" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/9/11">
        <title>Attitudes of dermatologists in the southeastern United States regarding treatment of alopecia areata: a cross-sectional survey study.</title>
        <description>Background:
Little evidence exists to guide treatment of alopecia areata (AA).  The current practices in treatment of children compared to adults and of progressive stages of hair loss are unknown.  The objective of this study was to examine the current practices of southeastern United States dermatologists for the treatment of AA.
Methods:
Dermatologists were sent anonymous questionnaires regarding their treatment practices by mail.  Respondents&apos; frequencies of treatment in children compared to adults and in patchy hair loss compared to widespread hair loss were compared with Wilcoxon signed-ranks tests and Friedman tests.  As a secondary source, the National Alopecia Areata Registry (NAAR) database was analyzed for patients&apos; treatment histories.
Results:
Survey results suggested that dermatologists recommend treatment less frequently for children than adults and for more advanced hair loss.  NAAR data confirmed that offering no treatment for AA is relatively common.
Conclusions:
Dermatologists&apos; treatment of AA is inconsistent.  A stronger evidence base will provide more consistent treatment options.</description>
        <link>http://www.biomedcentral.com/1471-5945/9/11</link>
                <dc:creator>Niyati Mukherjee</dc:creator>
                <dc:creator>Dean Morrell</dc:creator>
                <dc:creator>Madeleine Duvic</dc:creator>
                <dc:creator>Paul Stewart</dc:creator>
                <dc:creator>Lowell Goldsmith</dc:creator>
                <dc:source>BMC Dermatology 2009, 9:11</dc:source>
        <dc:date>2009-11-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-9-11</dc:identifier>
        <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>11</prism:startingPage>
        <prism:publicationDate>2009-11-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/9/10">
        <title>Professional use of the internet among Saudi Arabian
dermatologists: a cross-sectional survey</title>
        <description>Background:
The internet is an increasingly important tool for physicians, but the extent to which it is used by dermatologists is unknown. We aimed to investigate the utilization of the internet by dermatologists in Saudi Arabia for medical purposes during their daily practice and to clarify the reasons for its use and non-use.
Methods:
A self-administered questionnaire was distributed to all 160 dermatologists attending the National Dermatology conference in 2007.
Results:
A total of 107 questionnaires were completed. Sixty-two percent of respondents had access to the internet in the workplace. The use of the internet to update medical knowledge was reported by 91%.Only 27% had internet access in consultation rooms. The majority of information retrieval occurred outside patient consultation hours (91%).Only 13% reported using the internet during patient consultation. Possible reasons included: lack of access (54%), time pressure (37%), possible interference with the physician-patient relationship (30%), and that use of the internet was too time-consuming (10%). The mean searching time used to solve a clinical problem was 34 &#177; 3 minutes. Fifty-eight percent used Pubmed; however, 77% of the dermatologists had no training at all in how to use this tool.
Conclusion:
Professional medical use of the internet is widespread among dermatologists in Saudi Arabia. Providing access to the internet in the workplace and training of dermatologists to perform effective electronic searches are badly needed to improve the professional medical use of internet, which is expected to lead to better delivery of patient care.</description>
        <link>http://www.biomedcentral.com/1471-5945/9/10</link>
                <dc:creator>Khalid AlGhamdi</dc:creator>
                <dc:source>BMC Dermatology 2009, 9:10</dc:source>
        <dc:date>2009-10-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-9-10</dc:identifier>
        <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2009-10-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/9/9">
        <title>Volumizing effects of a smooth, highly cohesive, viscous 20-mg/mL hyaluronic acid volumizing filler: prospective European study</title>
        <description>Background:
Facial volume loss contributes significantly to facial aging. The 20-mg/mL hyaluronic acid (HA) formulation used in this study is a smooth, highly cohesive, viscous, fully reversible, volumizing filler indicated to restore facial volume. This first prospective study evaluated use in current aesthetic clinical practice.
Methods:
A pan-European evaluation conducted under guidelines of the World Association of Opinion and Marketing Research, the trial comprised a baseline visit (visit 1) and a follow-up (visit 2) at 14 &#177; 7 days posttreatment. Physicians photographed patients at each visit. Each patient was treated with the 20-mg/mL HA volumizing filler as supplied in standard packaging. Procedural details, aesthetic outcomes, safety, and physician and patient ratings of their experience were recorded.
Results:
Fifteen physicians and 70 patients (91% female; mean age: 50 years) participated. Mean volume loss at baseline was 3.7 (moderate) on the Facial Volume Loss Scale. Local anesthesia was used in 64.3% of cases. Most injections (85%) were administered with needles rather than cannulas. Of the 208 injections, 59% were in the malar region, primarily above the periosteum. Subcutaneous injections were most common for other sites. The mean total injection volume per patient was 4.6 mL. The mean volume loss score declined significantly (P &lt; .001) to 2.1 at visit 2. On the Global Aesthetic Improvement Scale, 88% and 76% of the treatments were rated very much improved or much improved by physicians and patients, respectively. Of the physicians, 95.6% rated this HA filler as very or fairly easy to use. Similarly, 92% of patients were very likely or quite likely to return for treatment; nearly all (98%) would recommend this treatment to friends. Transient (mean duration: 5.5 days) injection-site adverse events (AEs) occurred in 24 patients. Bruising was the most common AE.
Conclusion:
The 20-mg/mL smooth, highly cohesive, viscous, volumizing HA filler was effective, well tolerated, and easy to use in current clinical practice. Participants were very likely to recommend this product to colleagues and friends, and patients would be very or quite likely to request this product for future treatments.</description>
        <link>http://www.biomedcentral.com/1471-5945/9/9</link>
                <dc:creator>Klaus Hoffmann</dc:creator>
                <dc:creator>Juvederm Voluma Study Investigators Group (jvsig)</dc:creator>
                <dc:source>BMC Dermatology 2009, 9:9</dc:source>
        <dc:date>2009-08-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-9-9</dc:identifier>
        <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2009-08-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/9/8">
        <title>Familial keloids in five pedigrees: evidence for autosomal dominant inheritance and phenotypic heterogeneity</title>
        <description>Background:
Familial keloids have been reported, having either autosomal dominant or autosomal recessive inheritance. We wished to determine the inheritance pattern and phenotype of keloids among multigenerational families, as a prelude to a positional mapping strategy to identify candidate genes.
Methods:
We studied three African American families, one Afro-Caribbean family and one Asian-American family. Phenotyping including assessing all patients for the presence, distribution, and appearance of keloids, together with the timing of keloid onset and provocative factors. The clinical trial was registered at clinicaltrials.gov (NCT 00005802).
Results:
Age of keloid onset varied considerably within families, but commonly occurred by the second decade. The fraction of affected individuals was 38%, 45%, 62%, 67% and 73% among the five families respectively. Keloid severity and morphology differed within and between families. A novel finding is that certain families manifest keloids in distinct locations, with one family showing an excess of extremity keloids and two families showing an excess of axilla-groin keloids.
Conclusion:
Familial keloids appear to most commonly manifest autosomal dominant or semidominant inheritance, and there may be familial patterns of keloid distribution.</description>
        <link>http://www.biomedcentral.com/1471-5945/9/8</link>
                <dc:creator>Jason Clark</dc:creator>
                <dc:creator>Maria Turner</dc:creator>
                <dc:creator>Lillian Howard</dc:creator>
                <dc:creator>Horia Stanescu</dc:creator>
                <dc:creator>Robert Kleta</dc:creator>
                <dc:creator>Jeffrey Kopp</dc:creator>
                <dc:source>BMC Dermatology 2009, 9:8</dc:source>
        <dc:date>2009-07-28T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-9-8</dc:identifier>
        <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2009-07-28T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/9/7">
        <title>Role of the EGF +61A&gt;G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls.</title>
        <description>Background:
A single nucleotide polymorphism (61A&gt;G) in the epidermal growth factor (EGF) gene has been implicated in both melanoma pathogenesis and increased melanoma risk. To further evaluate this association, we conducted a case-control study in a clinic-based Italian population.
Methods:
Individuals with less than 10 (N = 127) or more than 100 (N = 128) benign nevi, and patients with cutaneous melanoma (N = 418) were investigated for the EGF +61A&gt;G polymorphism, using an automated sequencing approach.
Results:
Overall, no difference in EGF genotype frequencies was observed among subjects with different number of nevi as well as when non-melanoma healthy controls were compared with the melanoma patients. However, a heterogeneous distribution of the frequencies of the G/G genotype was detected among cases and controls originating from North Italy (21.1 and 18.3%, respectively) vs. those from South Italy (12.6 and 17.1%, respectively).
Conclusion:
Our findings further suggest that EGF +61A&gt;G polymorphism may have a limited impact on predisposition and/or pathogenesis of melanoma and its prevalence may vary in different populations.</description>
        <link>http://www.biomedcentral.com/1471-5945/9/7</link>
                <dc:creator>Milena Casula</dc:creator>
                <dc:creator>Mauro Alaibac</dc:creator>
                <dc:creator>Maria Pizzichetta</dc:creator>
                <dc:creator>Riccardo Bono</dc:creator>
                <dc:creator>Paolo Ascierto</dc:creator>
                <dc:creator>Ignazio Stanganelli</dc:creator>
                <dc:creator>Sergio Canzanella</dc:creator>
                <dc:creator>Grazia Palomba</dc:creator>
                <dc:creator>Edoardo Zattra</dc:creator>
                <dc:creator>The Italian Melanoma Intergroup (imi)</dc:creator>
                <dc:creator>Giuseppe Palmieri</dc:creator>
                <dc:source>BMC Dermatology 2009, 9:7</dc:source>
        <dc:date>2009-07-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-9-7</dc:identifier>
        <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2009-07-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/9/6">
        <title>A population-based survey on tanning bed use in Germany </title>
        <description>Background:
The suntanning industry has grown up over the last decade in Europe, mainly because tanned skin is considered socially desirable and attractive. Because of the potential negative impact of artificial tanning on public health, this study was to investigate tanning bed use behaviour, UV related risk perception and beliefs about tanning in the German population.
Methods:
In 2007, a representative telephone survey was carried out among 1501 German residents aged 14 years and older.
Results:
More than one fourth (28%) of the German population have used tanning beds at least once before in their lifetime. High-frequency tanning behaviour, i.e. using tanning beds more than 10 times per year, were recorded for 11%. Men and women aged 18 to 44 years and young women under the age of 18 used tanning beds more frequently (&gt;10 times per year). Tanning bed use was positively related to appearance and lifestyle related beliefs as well as to the perception that tanned skin is healthy.
Conclusion:
This analysis indicates that tanning bed use is common in Germany. The positive relationships of appearance and health related beliefs with tanning bed use are of great concern. The results indicate underlying misconceptions about the positive effect of artificial UV radiation compared to natural UV radiation particular for high-frequency tanners. The data shows the importance as well as the limitations for risk communication in its current effort to inform effectively about the dangers of artificial UV radiation.</description>
        <link>http://www.biomedcentral.com/1471-5945/9/6</link>
                <dc:creator>Franziska Borner</dc:creator>
                <dc:creator>Holger Schutz</dc:creator>
                <dc:creator>Peter Wiedemann</dc:creator>
                <dc:source>BMC Dermatology 2009, 9:6</dc:source>
        <dc:date>2009-07-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-9-6</dc:identifier>
        <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2009-07-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/9/5">
        <title>HLA-Cw*0602 associates with a twofold higher prevalence of positive streptococcal throat swab at the onset of psoriasis: a case control study</title>
        <description>Background:
The influence of streptococcal infections in the pathogenesis of psoriasis is not yet understood. In vitro data suggest that streptococcal factors influence T-cell function in psoriasis in a HLA-dependent manner, but studies designed to measure the HLA-C/Streptococci interaction are lacking. In the present study, we hypothesized that there is a statistical interaction between the result of streptococcal throat cultures and the presence of the HLA-Cw*0602 allele in psoriasis patients.
Methods:
We performed a case control study using the &quot;Stockholm Psoriasis Cohort&quot; consisting of patients consecutively recruited within 12 months of disease onset (Plaque psoriasis = 439, Guttate psoriasis = 143), matched to healthy controls (n = 454) randomly chosen from the Swedish Population Registry. All individuals underwent physical examination including throat swabs and DNA isolation for HLA-Cw*0602 genotyping.The prevalence of positive streptococcal throat swabs and HLA-Cw*0602 was compared between patients and controls and expressed as odds ratios with 95% confidence intervals. Associations were evaluated separately for guttate and plaque psoriasis by Fisher&apos;s exact test.
Results:
Regardless of disease phenotype, the prevalence of positive streptococcal throat swabs in HLA-Cw*0602 positive patients was twice the prevalence among HLA-Cw*0602 negative patients (OR = 5.8 C.I. = 3.57&#8211;9.67, p &lt; 0.001), while no difference was observed among Cw*0602 positive versus negative controls.The corresponding odds ratios for the guttate and plaque psoriasis phenotypes were 3.5 (CI = 1.5&#8211;8.7, p = 0.01) and 2.3 (CI = 1.0&#8211;5.1, p = 0.02) respectively.
Conclusion:
These findings suggest that among HLA-Cw*0602 positive psoriasis patients, streptococci may contribute to the onset or exacerbation of the inflammatory process independent of the disease phenotype. However, studies on the functional interaction between HLA-C and streptococcal factors are needed.</description>
        <link>http://www.biomedcentral.com/1471-5945/9/5</link>
                <dc:creator>Lotus Mallbris</dc:creator>
                <dc:creator>Katarina Wolk</dc:creator>
                <dc:creator>Fabio Sanchez</dc:creator>
                <dc:creator>Mona Stahle</dc:creator>
                <dc:source>BMC Dermatology 2009, 9:5</dc:source>
        <dc:date>2009-05-29T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-9-5</dc:identifier>
        <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2009-05-29T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/9/4">
        <title>Prevalence and characteristics of aquagenic pruritus in a young
African population
</title>
        <description>Background:
Aquagenic pruritus (AP) occurs during or after contact of the skin with water such as occurs in bathing.
Methods:
This study aims to describe the prevalence of aquagenic pruritus in a young adult population and describe the circumstances of bathing.A Population-based cross sectional study involving administration of Questionnaires to young adult Nigerians on the occurrence of pruritus associated with bathing.
Results:
The prevalence of bathing pruritus among respondents in this study was 23.8%. The commonest type of water respondents itch to was rain water (23%) followed by cold water (19%). 8.33% of respondents feels like avoiding bathing because of these.
Conclusion:
Bathing pruritus is a common finding among young adult Nigerians in the general population.</description>
        <link>http://www.biomedcentral.com/1471-5945/9/4</link>
                <dc:creator>T Salami</dc:creator>
                <dc:creator>S Samuel</dc:creator>
                <dc:creator>K Eze</dc:creator>
                <dc:creator>E Irekpita</dc:creator>
                <dc:creator>O Oziegbe</dc:creator>
                <dc:creator>M Momoh</dc:creator>
                <dc:source>BMC Dermatology 2009, 9:4</dc:source>
        <dc:date>2009-04-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-9-4</dc:identifier>
        <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2009-04-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/9/3">
        <title>Evaluation of the in vitro skin permeation of antiviral drugs from penciclovir 1% cream and acyclovir 5% cream used to treat herpes simplex virus infection</title>
        <description>Background:
Herpes simplex virus infection (HSV) is a common and ubiquitous infection of the skin which causes mucocutaneous lesions called cold sores (herpes labialis) or fever blisters. It is estimated that approximately 80% of the population worldwide are carriers of the Herpes simplex virus, approximately 40% suffer from recurrent recurrent infections. This study evaluates the in vitro skin permeation and penetration of penciclovir and acyclovir from commercialized creams for the treatment of herpes labialis (cold sores), using non viable excised human abdominal skin samples, which were exposed to 5 mg/cm2 of acyclovir 5% cream or penciclovir 1% cream.
Methods:
After 24 h of cream application, excess cream was washed off and layers of stratum corneum were removed by successive tape stripping. Amounts of active ingredients having penetrated through the skin were measured, as well as the amounts in the washed-off cream, in skin strips and creams remaining in the skin. Molecular modelling was used to evaluate physico-chemical differences between the drugs. Western blot analysis enabled to determine whether the marker of basal cells keratin 5 could be detected in the various tape strips.
Results:
Application of penciclovir 1% cream yielded higher concentration of drug in the deeper layers of the epidermis as well as a higher drug flux through the skin. Molecular modelling showed two higher hydrophobic moieties for acyclovir. Presence of the basal cell marker keratin 5 was underscored in the deeper tape strips from the skin, giving evidence that both drugs can reach their target cells.
Conclusion:
Penciclovir 1% cream has the tendency to facilitate the diffusion of the drug through the stratum corneum into the deeper epidermis layers, in which it could reach the target basal cells at effective therapeutical concentration. The small difference in the surface properties between both molecules might also contribute to favour the passage of penciclovir through the epidermis into the deeper basal cells.</description>
        <link>http://www.biomedcentral.com/1471-5945/9/3</link>
                <dc:creator>Nathalie Hasler-Nguyen</dc:creator>
                <dc:creator>Donald Shelton</dc:creator>
                <dc:creator>Gilbert Ponard</dc:creator>
                <dc:creator>Marlene Bader</dc:creator>
                <dc:creator>Martina Schaffrik</dc:creator>
                <dc:creator>Pascal Mallefet</dc:creator>
                <dc:source>BMC Dermatology 2009, 9:3</dc:source>
        <dc:date>2009-04-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-9-3</dc:identifier>
        <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2009-04-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/9/2">
        <title>Nonlinear modeling of venous leg ulcer healing rates</title>
        <description>Background:
The purpose of this manuscript was to determine whether the change in wound surface area over time could be described through nonlinear mathematics.
Methods:
We studied 3,588 serial wound tracings of 338 venous leg ulcers (VLUs) that had been followed during a controlled, prospective, randomized trial of two topical wound treatments.
Results:
A majority (72%) of VLUs exhibited surface area reduction via an exponential decay model, particularly during the early stages of healing. These results were consistent with the mechanics of wound contraction and epithelial cell proliferation, supported by the higher frequency at which exponential surface area reduction associated with full wound closure (35% of wounds that fit the exponential model healed vs. 21% of wounds that did not fit the exponential model completely healed during the study period, p = 0.018). Goodness-of-fit statistics suggested that much of the individual variation in healing could be described as nonlinear variation from the exponential model.
Conclusion:
We believe that parameter estimates from a mathematical model may provide a more accurate quantification of wound healing rates, and that similar models may someday reach routine use in comparing the efficacy of various treatments in routine practice and in product registration trials.</description>
        <link>http://www.biomedcentral.com/1471-5945/9/2</link>
                <dc:creator>Matthew Cardinal</dc:creator>
                <dc:creator>David Eisenbud</dc:creator>
                <dc:creator>David Armstrong</dc:creator>
                <dc:creator>Tania Phillips</dc:creator>
                <dc:creator>Keith Harding</dc:creator>
                <dc:creator>Jonathan Mansbridge</dc:creator>
                <dc:source>BMC Dermatology 2009, 9:2</dc:source>
        <dc:date>2009-03-31T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-9-2</dc:identifier>
        <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2009-03-31T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
